Oncology

The study will evaluate the safety, tolerability, and efficacy of the in combination in patients both with and without prior exposure to a KRASG12C inhibitor.

Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.

Opportunities for further optimization of CML management remain.

Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.

Heidi D. Finnes, PharmD, BCOP, FHOPA, president of HOPA discusses some key recommendations to women interested in pursuing leadership roles in oncology pharmacy.

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists and providers.

Omidubicel is a stem cell-based product that utilizes nicotinamide to inhibit differentiation and to increase the migration, bone marrow homing, and engraftment efficiency of hematopoietic progenitor cells.

New agents can offer a more tailored approach to therapy selection.

Selpercatinib is an oral selective RET kinase inhibitor approved for the treatment of metastatic RET fusion-positive non-small cell lung cancer and for metastatic thyroid cancer.

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.

For patients facing end-of-life care, psychedelic medicines may offer a chance to feel connected with themselves and others during such a difficult time.

Researchers identified a new immunotherapeutic target that may be effectively treated with CAR T-cell therapy in patients with pretreated multiple myeloma.

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

Higher C-reactive protein levels have been linked to cognition problems among older breast cancer survivors.

Two Houston Methodist cancer researchers were granted a quarter-million dollars each to study some of the most lethal forms cancer, including triple-negative breast cancer and multiple myeloma.

Yvonne Chen, PhD, discusses some of the strategies that researchers are using to improve T-cell effectiveness and overcome immunosuppression in CAR T-cell therapy.

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Relapses remain a challenge in treating patients with leukemia.

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

October is Breast Cancer Awareness Month.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.